The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo

Li, Wanyu; Ren, Ji-Hua; Tao, Na-Na; Ran, Long-Kuan; Chen, Xiang; Zhou, Hong-Zhong; Liu, Bo; Li, Xiaosong; Huang, Aiping; Chen, Juan

doi:10.1007/s00705-015-2712-8

Cited by 33 publications

(34 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is interesting that SIRT1 has been shown to play both pro-viral and anti-viral roles, depending on the type of virus. The SIRT1 inhibitor showed a suppressive effect on hepatitis B virus (HBV) replication [51,52], while the SIRT1 activator showed a suppressive effect on human T-cell leukemia virus type 1 (HTLV-1) [53] and MERS-CoV [54]. Han [55] found that SIRT1 inhibited viral RNA transcription and translation in enterovirus 71 (EV 71, a RNA virus)-infected human rhabdomyosarcoma (RD) cells.…”

Section: Discussionmentioning

confidence: 99%

“…The interactions between CC and APN, and GA and ACE2 were not included in our current analysis, mainly due to our strict rules for target screening. Through Venn analysis of targets from VCG Plus, silent mating type information regulation 2 homolog 1 (SIRT1) was found to only interact with GA. SIRT 1 belongs to the sirtuin family which contains seven proteins (SIRT1-7) that are class III NAD + -dependent histone deacetylases (HDACs) [51]. It is interesting that SIRT1 has been shown to play both pro-viral and anti-viral roles, depending on the type of virus.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Chen¹,

Hu²,

Hood

et al. 2020

Nutrients

119

View full text Add to dashboard Cite

Novel coronaviruses (CoV) have emerged periodically around the world in recent years. The recurrent spreading of CoVs imposes an ongoing threat to global health and the economy. Since no specific therapy for these CoVs is available, any beneficial approach (including nutritional and dietary approach) is worth investigation. Based on recent advances in nutrients and phytonutrients research, a novel combination of vitamin C, curcumin and glycyrrhizic acid (VCG Plus) was developed that has potential against CoV infection. System biology tools were applied to explore the potential of VCG Plus in modulating targets and pathways relevant to immune and inflammation responses. Gene target acquisition, gene ontology and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment were conducted consecutively along with network analysis. The results show that VCG Plus can act on 88 hub targets which are closely connected and associated with immune and inflammatory responses. Specifically, VCG Plus has the potential to regulate innate immune response by acting on NOD-like and Toll-like signaling pathways to promote interferons production, activate and balance T-cells, and regulate the inflammatory response by inhibiting PI3K/AKT, NF-κB and MAPK signaling pathways. All these biological processes and pathways have been well documented in CoV infections studies. Therefore, our findings suggest that VCG Plus may be helpful in regulating immune response to combat CoV infections and inhibit excessive inflammatory responses to prevent the onset of cytokine storm. However, further in vitro and in vivo experiments are warranted to validate the current findings with system biology tools. Our current approach provides a new strategy in predicting formulation rationale when developing new dietary supplements.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Chen¹,

Hu²,

Hood

et al. 2020

Nutrients

119

View full text Add to dashboard Cite

show abstract

“…Other ABC transporters (i.e., ABCA1 and ABCG1), which stimulate the cholesterol efflux [181], may also promote S1P enrichment of HDL-like lipoproteins [182,183]. More recently, it has been reported that ApoA-I promotes S1P release from endothelial cells via ABCA1 [184]. Despite this, the role of this transporter in plasma levels of S1P remains controversial.…”

Section: Atp-binding Cassette (Abc) Transportersmentioning

confidence: 99%

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Diarte-Añazco

Méndez-Lara

Pérez

et al. 2019

IJMS

View full text Add to dashboard Cite

Sphingolipids are key signaling molecules involved in the regulation of cell physiology. These species are found in tissues and in circulation. Although they only constitute a small fraction in lipid composition of circulating lipoproteins, their concentration in plasma and distribution among plasma lipoproteins appears distorted under adverse cardiometabolic conditions such as diabetes mellitus. Sphingosine-1-phosphate (S1P), one of their main representatives, is involved in regulating cardiomyocyte homeostasis in different models of experimental cardiomyopathy. Cardiomyopathy is a common complication of diabetes mellitus and represents a main risk factor for heart failure. Notably, plasma concentration of S1P, particularly high-density lipoprotein (HDL)-bound S1P, may be decreased in patients with diabetes mellitus, and hence, inversely related to cardiac alterations. Despite this, little attention has been given to the circulating levels of either total S1P or HDL-bound S1P as potential biomarkers of diabetic cardiomyopathy. Thus, this review will focus on the potential role of HDL-bound S1P as a circulating biomarker in the diagnosis of main cardiometabolic complications frequently associated with systemic metabolic syndromes with impaired insulin signaling. Given the bioactive nature of these molecules, we also evaluated its potential of HDL-bound S1P-raising strategies for the treatment of cardiometabolic disease.

show abstract

“…SIRT‐1 inducer resveratrol had been shown to influence the HBV replication . Recently, the inhibition of the SIRT‐1 has been reported to inhibit the HBV replication . Therefore, targeting SIRT‐1 expression in the HBV infected cells might have antiviral activity.…”

Section: Introductionmentioning

confidence: 99%

Butyrate inhibits HBV replication and HBV‐induced hepatoma cell proliferation via modulating SIRT‐1/Ac‐p53 regulatory axis

Pant

Mishra

Pradhan

et al. 2018

Molecular Carcinogenesis

View full text Add to dashboard Cite

Butyrate, a histone deacetylase inhibitor, has several therapeutic applications, including cancer. However, the effect of butyrate in HBV replication is not known so far. It was hypothesized that butyrate might inhibit HBV replication and host cell proliferation via SIRT-1. It was found that the increased expression of SIRT-1 in Hep G2.2.15 cells (HBV expressing cells) than Hep G2 cells. Next the expression of SIRT-1 and Acetylated p53 (Ac-p53) were measured in the liver biopsy samples of chronic hepatitis B (CHB) patients with high viral load and compared to CHB patients with low viral load and found that there was a high SIRT-1 expression and a low Ac-p53 levels in CHB patients with high viral load compared to CHB patients with low viral load. Incubation of butyrate inhibited SIRT-1 expression and cell proliferation. Inhibition of SIRT-1 by butyrate or SIRT-1 siRNA increased the levels of Ac-p53. The elevated Ac-p53 decreased p-akt, cyclin D1, and thereby inhibited cell proliferation. Incubation of butyrate with Hep G2.2.15 cells also inhibited HBx protein expression, HBV-DNA and hepatitis B surface antigen (HBsAg). Taken together, the data showed that butyrate inhibited HBV replication and cell proliferation by inhibiting SIRT-1 expression in hepatoma cells. K E Y W O R D S anti-viral, butyrate, HBV, p53, replication, SIRT-1 1 | INTRODUCTION Hepatitis B Virus (HBV) is a small double stranded-DNA virus, and its infection is a major health problem worldwide. 1 HBV infection is responsible for chronic liver inflammation (hepatitis), which further progresses to liver cirrhosis and liver failure or hepatocellular carcinoma (HCC). 2 The control of HBV replication is one of the most significant approaches to reduce the chronic HBV infection-linked pathogenicity. To date, there is no treatment available which can completely eradicate HBV infection in the patients. Few chemotherapeutic drugs such as, adefovir, entecavir, lamivudine, and telbivudine target the HBV-DNA polymerase and can reduce the viral replication. 3,4 However, long-term use of these drugs might lead to the increase the viral drug-resistance. 4Recently, use of interferon-alpha (IFN-α) along with the analogues of nucleotide/nucleoside significantly minimized the HBV infection and replication in the HBV infected patients. 5,6 Nevertheless, long-term use of IFN-α and nucleotide/nucleoside therapy tends to develop the drug resistance and causes some side effects in the patients. 7,8 Therefore, there is a need for a potential therapy or the targeted drugs for the anti-HBV therapeutics.SIRT-1 or Sirtuin-1 is a class III histone deacetylase (HDAC), which can deactivate histones or many non-histone proteins including p53, NF-κB, AP-1, and PGC-1α. SIRT-1 modulates several cellular processes such as apoptosis, cell cycle regulation, aging, and gene silencing. 9-11 SIRT-1 is also known to induce HBV replication. 12 SIRT-1 inducer resveratrol had been shown to influence the HBV

show abstract

The SIRT1 inhibitor, nicotinamide, inhibits hepatitis B virus replication in vitro and in vivo

Cited by 33 publications

References 34 publications

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Novel Insights into the Role of HDL-Associated Sphingosine-1-Phosphate in Cardiometabolic Diseases

Butyrate inhibits HBV replication and HBV‐induced hepatoma cell proliferation via modulating SIRT‐1/Ac‐p53 regulatory axis

Contact Info

Product

Resources

About